Akero Therapeutics, Inc.
AKRO
Peringkat dalam Saham
#3738
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Harga Saham
$54.65
Terakhir disinkronkan: 2025-12-09
Kapitalisasi Pasar
$4.50B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
1.37%
Negara
US
Perdagangan Akero Therapeutics, Inc. (AKRO)
Kategori
Healthcare
Jumlah saham beredar untuk Akero Therapeutics, Inc. (AKRO)
Jumlah saham beredar per September 2025: 82.01M
Menurut laporan keuangan terbaru dan harga saham Akero Therapeutics, Inc., jumlah saham beredar saat ini adalah 82.01M. Pada akhir December 2023, perusahaan memiliki 52.57M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Akero Therapeutics, Inc. (AKRO) dari 2017 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 82.01M | 22.15% |
| 2024 | 67.14M | 27.71% |
| 2023 | 52.57M | 34.84% |
| 2022 | 38.98M | 11.94% |
| 2021 | 34.83M | 10.69% |
| 2020 | 31.46M | 108.77% |
| 2019 | 15.07M | -28.99% |
| 2018 | 21.22M | -25.67% |
| 2017 | 28.56M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | 209.60% |
US
|
|
| 396.00M | 382.88% |
US
|
|
| 478.91M | 483.98% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -24.17% |
NL
|
